Skip to main content

Analgetika

  • Chapter

Zusammenfassung

Für die Schmerzbehandlung werden in erster Linie Opioide und nichtopioide Analgetika eingesetzt. Nichtopioide Analgetika wirken zusätzlich antipyretisch, einige auch entzündungshemmend. In manchen Fällen bereitet es Schwierigkeiten, eine eindeutige Trennung von Analgetika gegenüber den Antirheumatika und Antiphlogistika vorzunehmen. Seit mehreren Jahren werden die nichtsteroidalen Antiphlogistika Ibuprofen, Naproxen und Diclofenac in geringerer Dosis auch als rezeptfreie Schmerzmittel verwendet.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (1986): Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Ärztebl 83: 3267.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2007a): Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. Internet: www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf

  • Arzneimittelkommission der deutschen Ärzteschaft (2007b): Leberschäden unter Flupirtin. Dtsch Ärztebl 104: A3200.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2012): Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen. Dtsch Ärztebl 109: A724–A725.

    Google Scholar 

  • Bornemann-Cimenti H, Wejbora M, Szilagyi I, Sandner-Kiesling A (2013): Fentanyl zur Behandlung von tumorbedingten Durchbruchschmerzen. Dtsch Ärztebl 110: 271– 277.

    Google Scholar 

  • Budd K (1990): Experience with partial antagonists in the treatment of cancer pain. In: Doyle D (Ed). Opioids in the treatment of cancer pain. Royal Society of Medicine, International Congress and Symposium Series No. 146, pp. 51–54.

    Google Scholar 

  • Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005): Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825–834.

    Article  PubMed  CAS  Google Scholar 

  • Devulder J (2010): Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 24: 867–881.

    Article  PubMed  CAS  Google Scholar 

  • Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002): Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97: 827–836.

    Article  PubMed  CAS  Google Scholar 

  • Frampton JE (2010): Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70: 1719–1743.

    Article  PubMed  CAS  Google Scholar 

  • Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006): Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174: 1589–1594.

    Article  PubMed  Google Scholar 

  • Garbe E, Jobski K, Schmid U (2012): Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198.

    Article  PubMed  Google Scholar 

  • Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001): Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593.

    Google Scholar 

  • Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994): Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94-0592, March, Rockville.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2012a): Oxycodon/Naloxon. Wirkstoff aktuell Ausgabe 6/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Oxycodon-Naloxon.pdf

  • Kassenärztliche Bundesvereinigung (2012b): Tapentadol. Wirkstoff aktuell Ausgabe 3/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Tapentadol.pdf

  • Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009): A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13: 56–64.

    Article  PubMed  CAS  Google Scholar 

  • Mercadantes S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C, Giarratano A, Casuccio A (2012): Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 28: 1775–1779.

    Article  Google Scholar 

  • Radbruch L, Elsner F (2005): Palliative Schmerztherapie, Cannabinoide. Internist 46: 1105-1114.

    Article  PubMed  CAS  Google Scholar 

  • Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006): Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14: 400–407.

    Article  PubMed  Google Scholar 

  • Quigley C (2002): Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002 (1): CD003447.

    Google Scholar 

  • Schubert I, Ihle P, Sabatowski R (2013): Zunahme der Opioidverordnungen in Deutschland zwischen 2000 und 2011. Dtsch Ärztebl 110: 45–51.

    Google Scholar 

  • Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC (2008): Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 138: 440–449.

    Article  PubMed  Google Scholar 

  • The Pain Society (2004): Recommendations for the appropriate use of opioids for persistent non-cancer pain. A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. March 2004. Internet: www.britishpainsociety.org/pdf/opioids_doc_2004.pdf

  • Wilcock A (2009): Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 13: 1001 (2009).

    Google Scholar 

  • World Health Organization (WHO) (1986): Cancer Pain Relief. World Health Organization Publications, Geneva, Switzerland.

    Google Scholar 

  • World Health Organization (WHO) (1996): Cancer pain relief, 2nd edn. World Health Organization Publications, Geneva, Switzerland.

    Google Scholar 

  • Zhang WY, Po AL (1996): Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain – a metaanalysis. J Clin Pharm Ther 21: 261–282.

    Article  PubMed  CAS  Google Scholar 

  • Zhang WY, Po AL (1997): Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 22: 79–97.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Böger, R.H., Schmidt, G. (2013). Analgetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics